Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CRBP 
Corbus Pharmaceuticals Holding (CRBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/11/2025: CRBP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $45.11
Year Target Price $45.11
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 624.16% | Avg. Invested days 49 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 90.55M USD | Price to earnings Ratio - | 1Y Target Price 42.89 |
Price to earnings Ratio - | 1Y Target Price 42.89 | ||
Volume (30-day avg) - | Beta 3.12 | 52 Weeks Range 4.64 - 61.90 | Updated Date 06/29/2025 |
52 Weeks Range 4.64 - 61.90 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.18% | Return on Equity (TTM) -44.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -38278616 | Price to Sales(TTM) 163.32 |
Enterprise Value -38278616 | Price to Sales(TTM) 163.32 | ||
Enterprise Value to Revenue 8.26 | Enterprise Value to EBITDA 0.17 | Shares Outstanding 12236800 | Shares Floating 7524021 |
Shares Outstanding 12236800 | Shares Floating 7524021 | ||
Percent Insiders 0.71 | Percent Institutions 93.23 |
Analyst Ratings
Rating 4.7 | Target Price 45.11 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Corbus Pharmaceuticals Holding
Company Overview
History and Background
Corbus Pharmaceuticals Holdings, Inc. was founded in 2009. It is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory, fibrotic, and metabolic diseases. The company has shifted its focus over time based on clinical trial results.
Core Business Areas
- Pharmaceutical Development: Focuses on developing and commercializing therapeutics for inflammatory, fibrotic, and metabolic diseases. Current focus is on CRB-701, a novel ADC targeting Nectin-4 expressing tumors.
Leadership and Structure
Yuval Cohen, Ph.D., is the Chief Executive Officer. The company has a board of directors and a management team responsible for overseeing its operations.
Top Products and Market Share
Key Offerings
- CRB-701: CRB-701 is an antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of tumors expressing this protein. As it is in early clinical stages, market share and revenue data are not yet available. Potential competitors include other companies developing ADCs targeting similar cancer indications, like Seagen (SGEN) and Astellas (ALPMY) with Padcev.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive. It involves the discovery, development, manufacturing, and marketing of drugs. The ADC market is rapidly growing.
Positioning
Corbus is a clinical-stage biopharmaceutical company aiming to develop novel therapeutics. Its competitive advantage lies in its proprietary ADC platform and its focus on targeting specific disease pathways.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is substantial, reaching hundreds of billions of dollars globally. Corbus is positioned to potentially capture a portion of this market with successful development and commercialization of CRB-701.
Upturn SWOT Analysis
Strengths
- Novel ADC technology platform
- Experienced management team
- Strong focus on specific disease targets
- Potential for first-in-class therapeutics
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- No currently marketed products
- High risk of failure in drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through further research
- Positive clinical trial results
- Addressing unmet medical needs
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- SGEN
- ALPMY
- MRNA
- PFE
Competitive Landscape
Corbus faces significant competition from established pharmaceutical companies with greater resources. Its success depends on the differentiation and efficacy of its ADC technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in R&D spending and pipeline development.
Future Projections: Future growth is contingent on successful clinical trials and potential commercialization of CRB-701.
Recent Initiatives: Recent initiatives include advancing CRB-701 through clinical trials and exploring potential partnerships.
Summary
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company with a novel ADC technology platform. Its future is highly dependent on the success of CRB-701's clinical trials. Competition is strong from larger firms with more resources. Corbus's lack of marketed products and reliance on clinical trial outcomes present substantial risks. Positive trial data is critical for attracting partnerships and achieving commercial success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings, Press Releases, Industry Reports
- Yahoo Finance
- Google Finance
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial professional. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corbus Pharmaceuticals Holding
Exchange NASDAQ | Headquaters Norwood, MA, United States | ||
IPO Launch date 2014-11-11 | CEO & Director Dr. Yuval Cohen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.corbuspharma.com |
Full time employees 28 | Website https://www.corbuspharma.com | ||
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.